Hims & Hers Health, Inc. $HIMS Holdings Decreased by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 60.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 29,394 shares of the company’s stock after selling 45,010 shares during the period. GF Fund Management CO. LTD.’s holdings in Hims & Hers Health were worth $954,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quent Capital LLC bought a new stake in shares of Hims & Hers Health during the third quarter valued at about $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Hims & Hers Health during the fourth quarter valued at about $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health during the third quarter valued at about $28,000. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the first quarter valued at about $30,000. Finally, Hilltop National Bank bought a new stake in shares of Hims & Hers Health during the third quarter valued at about $35,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $28.74 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The company’s 50-day moving average price is $19.72 and its two-hundred day moving average price is $32.28. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The stock has a market cap of $6.55 billion, a PE ratio of 56.35, a price-to-earnings-growth ratio of 2.56 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The firm had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. During the same period in the previous year, the business earned $0.11 earnings per share. Hims & Hers Health’s revenue for the quarter was up 28.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Irene Becklund sold 5,529 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the transaction, the insider owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This trade represents a 38.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 4,812 shares of Hims & Hers Health stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $118,808.28. Following the completion of the transaction, the insider directly owned 308,831 shares in the company, valued at $7,625,037.39. This represents a 1.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 129,889 shares of company stock worth $3,230,986. Company insiders own 13.71% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Regulatory catalyst — the FDA has begun a formal review process and scheduled advisory meetings to consider allowing compounding pharmacies to make several popular peptides, which could expand addressable market for Hims if it participates in peptide products or distribution. Hims rises as FDA considers broader peptides access
• Positive Sentiment: Investor enthusiasm and coverage lift — multiple outlets tied comments from RFK Jr. and the FDA step to a clearer path for peptide access, helping the stock to rally as traders price in new revenue opportunities. Hims jumps as RFK Jr. seeks to loosen peptide regulations
• Positive Sentiment: Street reaction — Bank of America raised its price target to $25 (from $21) citing the peptide review as a potential long‑term tailwind, a move that helped validate the bull narrative even though the rating stayed Neutral. BofA Raises Hims & Hers Target to $25
• Neutral Sentiment: Momentum/volume — the stock has seen an intraday surge with above‑average volume, but some analyst notes warn that recent EPS/estimate revisions may not guarantee sustained upside. Monitor whether revisions follow through. Hims & Hers Soars 11.1%
• Neutral Sentiment: Valuation questions — commentary urging a reassessment of HIMS highlights sharp short‑term moves and mixed longer‑term returns; valuation metrics and elevated beta increase sensitivity to news flow. Is It Time To Reassess Hims & Hers?
• Negative Sentiment: Short interest / hedge fund activity — Cedar Grove Capital disclosed a profitable short stance and highlighted downside in its investor letter, underscoring persistent bearish views among some investors. Cedar Grove Capital Benefitted from Short Position
• Negative Sentiment: Broader fundamental concerns — coverage noting that HIMS has fallen substantially over recent months and faces margin and cash‑flow pressure suggests downside risk remains if regulatory optimism fades or execution slips. HIMS Plunges 51.2% in 6 Months

Analyst Ratings Changes

A number of brokerages recently weighed in on HIMS. Barclays lifted their price objective on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Citigroup upgraded shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, April 11th. Finally, Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $31.86.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.